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Abstract
Background: People who present to hospital after intentionally harming themselves pose a common and
important problem. Previous reviews of interventions have been inconclusive as existing trials have been under
powered and done on unrepresentative populations. These reviews have however indicated that problem solving
therapy and regular written communications after the self-harm attempt may be an effective treatment. This
protocol describes a large pragmatic trial of a package of measures which include problem solving therapy, regular
written communication, patient support, cultural assessment, improved access to primary care and a risk
management strategy in people who present to hospital after self-harm using a novel design.
Methods: We propose to use a double consent Zelen design where participants are randomised prior to giving
consent to enrol a large representative cohort of patients. The main outcome will be hospital attendance following
repetition of self-harm, in the 12 months after recruitment with secondary outcomes of self reported self-harm,
hopelessness, anxiety, depression, quality of life, social function and hospital use at three months and one year.
Discussion: A strength of the study is that it is a pragmatic trial which aims to recruit large numbers and does not
exclude people if English is not their first language. A potential limitation is the analysis of the results which is complex
and may underestimate any effect if a large number of people refuse their consent in the group randomised to
problem solving therapy as they will effectively cross over to the treatment as usual group. However the primary
analysis is a true intention to treat analysis of everyone randomised which includes both those who consent and do
not consent to participate in the study. This provides information about how the intervention will work in practice in a
representative population which is a major advance in this study compared to what has been done before.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000641291
Background
Hospital attendance following self-harm is important
because it is common, and it is a risk for subsequent
suicide and for increased mortality from all causes. In
2006 there were 5400 hospitalisations for intentional
self-harm in New Zealand, equating to an annual rate of
151.7 per 100,000 population [1]. However this figure is
likely to be a considerable underestimate as a result of
the way the data are collected with different hospitals
having different rules about what is counted as a hospi-
talisation and different ways of coding self-harm. In
other countries self-harm is one of the commonest rea-
sons for presentation to the emergency department [2].
Self-harm is also important because of the link to sui-
cide. About 1% of people who self-harm will go onto
kill themselves during the next year, and a person’sr i s k
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any medium, provided the original work is properly cited.of suicide following self-harm is about 100 times that of
the general population[3]. Lastly there is also a signifi-
cant increase in premature mortality from other causes
with up to 10% of people who present to hospital with
self-harm being dead after five years with about half this
premature mortality being due to physical disorders [4].
From a public health perspective, people who are
admitted to hospital with intentional self-harm are an
easily identifiable high-risk group, who are usually not
currently in contact with health services [5], which
makes this a timely opportunity for intervention particu-
larly around suicide prevention.
Why a complex intervention?
Current research indicates that there are several promis-
ing areas to focus on improving outcomes after self-
harm.
Firstly there is regular written communication sent to
patients after the episode of self-harm. In 2005 Carter and
colleagues developed an intervention in which a series of
eight “postcards” were sent in sealed envelopes over one
year after discharge to patients who had presented at
emergency departments for self-poisoning[6]. At one year
follow-up patients in the intervention group had half the
number of readmissions than the control group (101 ver-
sus 192) although the proportion of people re-presenting
in each group was not significantly different, suggesting
that any effect was attributable to reduction in multiple
readmissions in a small group of patients. In a more recent
trial in Christchurch by Annette Beautrais [7] of a similar
intervention there was no difference in outcomes once the
history of self-harm had been taken into account in both
groups. However the study sample was small and included
people presenting to a crisis team with suicidal ideas as
well as presentations with self-harm to the emergency
department.
Secondly there is problem-solving therapy (PST)
which is a brief focused psychological treatment that has
been shown to be significantly more effective than con-
trol conditions with regard to improvement in depres-
sion, hopelessness and problems in patients who have
attended hospital after self-harm[8]. Evidence that pro-
blem solving therapy is effective in reducing repetition
rates is less conclusive, although promising trends have
been reported[9]. There is general agreement that pro-
blem solving therapy is a cost-effective, brief interven-
tion that has the potential to be a feasible and effective
addition to existing services[8].
N e x ti st h ei s s u eo ft h eh i g hm o r t a l i t yr a t ef r o mn o n
suicide causes after self-harm. About 50% of the prema-
ture mortality after self-harm is due to non suicide
deaths[10] and the overall rate of death may reach 15%
five years after the index episode of self-harm[4]. This
suggests that treating self-harm as purely a mental
health problem will not address a key outcome as
potentially modifiable non-mental health issues may be
missed.
A related problem is the issue of patients not getting
the treatment outlined in management plans made in
the emergency department, perhaps because of patients’
resistance to attend appointments, referrals not being
made in a timely fashion or contact details recorded in
the emergency department being incorrect. There is
some evidence that more intensive outreach after self-
harm results in better attendance in out-patients
although it is unclear whether this decreases the repeti-
tion rate[9].
A difficult and controversial area is the management
of risk for the individual and the team. Traditionally risk
assessment in mental health, especially in the area of
suicide prevention, has focused on prediction, using risk
factors associated with the patient, so that patients are
said to be at low, medium and high risk. The difficulty
with this is that there is no evidence that clinicians can
predict who will die by suicide, most people who kill
themselves are low risk and most people who are high
risk don’t kill themselves[11]. This suggests that using
risk assessment to predict who will kill themselves is
flawed and that a better system is needed.
Lastly a neglected component of assessment in mental
health, with the notable exception of ‘cultural services”,
is the clinical assessment of identity and belonging in
people who self-harm. (Cultural services in New Zealand
are clinical services largely run by and for certain ethnic
groups, in particular Maori in accordance with the
Treaty of Waitangi). This is particularly surprising given
that having a damaged autobiographical memory[12]
and a poor sense of belonging[13] are relatively com-
mon in people who self-harm. For this reason we pro-
pose as part of the “package of care” that everybody
receives a “cultural assessment” to assess their sense of
belonging and for those who receive problem solving
they will be prompted to consider “not belonging” as a
potential problem. “Not belonging” can be operationa-
lised as being socially isolated which can potentially be
addressed by problem solving therapy.
We propose to include each of these components in a
package of care delivered to individuals after they pre-
sent with self-harm. By combining them together we
aim to replicate the package of interventions that a clini-
cal “self-harm team” could reasonably deliver and to test
the idea that the effect of the package is more than the
sum of the individual parts. The parts of the package
will be sending postcards over a year; the offer of brief
problem solving therapy; patient support which will be a
mainly telephone based system of case management to
“stop people falling through the cracks” after their pre-
sentation to hospital; vouchers that will allow patients to
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emphasis on physical health checks and ensuring regis-
tration with a GP; a systemic approach to identifying
and managing modifiable risk factors in the patient and
the self-harm team based on the principles successfully
used in managing risk in aviation; and a cultural assess-
ment focused on sense of belonging.
Why use a Zelen design?
Systematic reviews have identified small randomised
trials of unrepresentative patients as a problem in this
area. This study uses a double consent Zelen randomi-
sation design. In this design individuals are randomised
before they give consent. The reason for choosing this
design, rather than the standard randomised controlled
trial design, is that in a standard randomised con-
trolled trial clients are required to understand complex
concepts such as randomisation and clinical equipoise
before giving consent so that in effect they are asked
to consent to randomisation rather than a particular
intervention. Such an approach is likely to be inap-
propriate for people in crisis, in an emergency room,
and who are often physically unwell following a self-
harm episode[14]. Consequently the use of a Zelen
design has the potential to improve recruitment rates
[15] as the conversation with eligible patients is sim-
pler as patients are offered the choice of accepting or
declining the treatment they have been offered. Also
the people who consent to randomisation in conven-
tional trials may well be unrepresentative of the people
who present following self-harm [9]. More importantly,
if people are offered the possibility of receiving pro-
blem-solving therapy but then find that they have been
randomised to receive treatment as usual only, this
may result in higher rates of non-compliance in the
control group as well as the possibility of “resentful
demoralisation” [16], resulting in higher drop-out rates
from the control group or reporting of worse out-
comes on self-completed measures.
The study aim is to investigate the effectiveness of a
package of care plus treatment as usual compared to
treatment as usual in people who presented to hospital
after self-harm. Specifically we have the following
hypotheses:
1. The package of care plus treatment as usual is
more effective than treatment as usual in reducing
hospital re-attendance for self-harm in the first year.
This is the primary outcome.
2. The package of care plus treatment as usual is
more effective than treatment as usual in reducing
self-reported repetition of self-harm hopelessness,
depression, anxiety and health service use at three
months and one year.
3. The package of care plus treatment as usual will
improve quality of life and function at three months
and one year compared to treatment as usual.
4. The package of care will be more cost effective
than treatment as usual.
Methods
Design
We will use a Zelen randomised controlled design to
compare the package of care plus treatment as usual to
treatment as usual in people who presented to hospital
with self-harm.
Setting
The study will be conducted in four hospitals in three
District Health Boards (DHB) in New Zealand - Waite-
mata DHB (North Shore Hospital and Waitakere Hospi-
tal), Counties Manukau DHB (Middlemore Hospital)
and Northland DHB (Whangarei Hospital). Waitemata
DHB provides health services for a population of about
525,000 people in urban north and west Auckland and a
rural area north of the city with about 17% of its popu-
lation living in the most deprived areas; Counties Manu-
kau provides health care for 470,000 people in the South
of Auckland and serves a population that is relatively
young with a high proportion of Maori and recent
immigrants and about a third of the population living in
areas that are very deprived (http://www.cmdhb.org.nz/
about_cmdhb/overview/population-profile.htm); North-
land DHB serves a mainly rural area of about 150,000
characterised by a large Maori population, widely dis-
persed rural communities and a disproportionately high
level of socio-economic deprivation.
Participants
Patients who present to hospital through the emergency
department after self-harm will be eligible if they are
not at school and are able to give informed consent.
Patients who require an interpreter will be included in
the study.
Potential participants will be excluded if they are aged
under 17; are still at school; are unable to give informed
consent to be part of the study, that is, if they are too
mentally unwell (for example they are psychotic or
hypomanic); if they are too physically unwell (for exam-
ple, they are in a coma or with lowered level of con-
sciousness); or if they are severely cognitively impaired.
People who identify as Maori will be recruited into Te
Ira Tangata the “sister-study” to ACCESS which is a
Zelen randomised controlled trial that will be offering a
culturally appropriate intervention to Maori who present
with self-harm. There will be times (at the start of the
ACCESS trial) and places where Te Ira Tangata will not
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w i l lb er e c r u i t e di n t oA C C E S S .T h i sw i l le n a b l eu st o
access the impact of a Maori team versus a mainstream
service on the engagement, management and outcomes
of Maori who present with self-harm.
Self-harm is defined as intentional self-poisoning or
self-injury, irrespective of motivation. Self-poisoning
includes the intentional ingestion of more than the pre-
scribed amount of any drug, whether or not there is evi-
dence that the act was intended to result in death. This
also includes poisoning with non-ingestible substances
(for example pesticides or carpet cleaner), overdoses of
‘recreational drugs’ and severe alcohol intoxication
where the clinical staff considers such cases to be an act
of intentional self-harm. Self-injury is defined as any
injury that has been intentionally self-inflicted [17].
We will assess the degree of suicidal intent by using a
modified self report version of the Beck Suicide Intent
Scale which we will use in the analysis to assess the
impact suicidal intent on outcomes.
Recruitment
Following a psychosocial assessment by a non-study
mental health clinician, patients will be handed a card
by non-study clinician which informs them that they
will be approached to participate in a study about what
happens after self-harm (see Additional File 1). If
patients do not want to be contacted they will be asked
to inform one of the non-study staff. Eligibility for the
study will be assessed by a research therapist reviewing
the notes. Eligible patients will be randomised and then
approached by the research clinician to explain the
study and to request consent to participate.
The maximum delay between the psychosocial assess-
ment and the attempt to obtain consent is four days to
allow for weekends and public holidays when research
staff are not available. In practice we aim to approach
potential participants within 24 hours of their presenta-
tion to the hospital. The approach will occur either
within the Emergency Department, in hospital if the
person is admitted, or where necessary, by telephone
after the patient is discharged. An interpreter will be
made available to any person who requests one.
Randomisation and blinding
As this is a Zelen trial randomisation will be prior to
obtaining consent. All eligible participants are allocated
randomly to the intervention or usual care groups using a
central computerised randomisation system at the Clinical
Trials Research Unit (http://www.ctru.auckland.ac.nz). Stra-
tified minimisation randomisation will be used to ensure a
balance in key prognostic factors between the study groups:
site (Waitemata DHB, Counties Manukau DHB, Northland
DHB), history of self-harm (none, repeater), and method of
self-harm (overdose, self injury, both). The assessors will
be blind to the intervention group at the three and twelve
months follow up assessments.
Intervention group
People who are randomised and consent to receive the
intervention will receive a six element package of care
comprised of:
1 .P a t i e n ts u p p o r tf o ru pt ot w ow e e k s .T h i sw i l l
consist of one or two face-to-face or telephone ses-
sions depending on patient preference and feasibility
over the two week period following the participant’s
discharge from hospital. These sessions will involve
obtaining the discharge plan developed by the asses-
sing clinicians, checking that the patient understands
it, identifying potential barriers to implementation of
the plan and assisting the patient to follow through
with the plan. In other words, the primary aim of
patient support will be to ensure patients do not
“fall through the cracks”. The research clinicians will
be expected to liaise with the mental health crisis
and community mental health teams; alcohol and
drug services; primary care and non health services.
Each patient support session will include a risk
assessment asking about thoughts and plans for self-
harm. If a patient is identified as being at risk of
self-harm the risk management protocol will be
followed.
2. Postcard contact for one year. Eight postcards will
be sent in sealed envelopes in months 1,2,3,4,6,8,10
and 12 after the index episode. The cards will con-
tain a short message stating that we hope things are
going well and inviting them to write us a note if
they wish to (see Additional File 2). Each envelope
will contain a return stamped addressed envelope.
3. Problem solving therapy. This will consist of up to
four to six sessions in the four weeks after the parti-
cipant’s index presentation to hospital for self-harm.
Research clinicians will assess the participant’s elig-
ibility for brief problem solving therapy prior to and
at the initial patient support session. Patients may be
ineligible for brief problem solving therapy if they
are already receiving psychotherapy (for example if
they are receiving Dialectical Behaviour Therapy), if
brief problem solving therapy would contradict their
management plan, if they live or are moving out of
area, if they are in prison or if there is a risk of
harm to the research clinician. The problem solving
therapy we will use in the treatment package will be
conducted with individual patients and is based on
the model originally defined by D’Zurilla and Gold-
fried [18]. Problem solving therapy sessions will aim
to teach the person to recognise and identify current
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approach to problem solving. A clinician manual
and a participant workbook will be used by the
research team to guide the structure of problem sol-
ving therapy sessions. Sessions will be audiotaped.
4. Improved access to primary care. We will encou-
rage participants to attend their GP for a physical
health check paying particular attention to cardio-
vascular risk factors especially alcohol and smoking.
We will use GP vouchers to facilitate these visits.
5. A risk management strategy. The teams will
also pilot a risk management strategy around the
management of suicidal patients. This will consist
of a checklist for patient support to ensure that
key tasks are completed and questions asked. Sec-
ondly the research team will meet once a week to
discuss adverse events defined as repeat episodes
of self-harm, hospital re presentation for any rea-
son and suicides. A record will be kept of these
discussions, including any changes to process as a
result of these discussions, and circulated to the
team in the form of a “risk bulletin”. The research
team will also receive training in crew resource
management.
6. Cultural assessment. We have two aims here, the
first is to increase the number of people who receive
cultural services after self-harm. From our previous
study we found that the input of Maori services after
self-harm was very rare. While we are recruiting
Maori participants into the trial (prior to Te Ira
Tangata starting or at sites where Te Ira Tangata is
not running), cultural services may involve liaising
with Maori non government organizations and
Maori mental health services. Throughout the study
the cultural assessment will involve liaising with
Pacific Island and Asian services if appropriate. The
second aim will be to complete a cultural assessment
on everyone (that is including people of European
descent) paying particular attention to the sense of
belonging and feelings around ethnicity. Problems
with sense of belonging will be included in the pro-
blem solving checklist for patients.
Treatment as Usual
Treatment as usual following self-harm varies and may
involve referrals to multi-disciplinary teams for psychia-
tric or psychological intervention, referrals to crisis
teams and/or recommendations for engagement with
community alcohol and drug treatment centres. The dis-
charge plan may include referrals to more than one
health care provider, or may consist solely of referral
back to the patients’ General Practitioner.
Treatment as usual assessment
Treatment as usual for all participants will be assessed
by self report using a written questionnaire and tele-
phone interview by a research assistant blind to treat-
ment allocation; a review of DHB records; and by using
the National Minimum Dataset from the Ministry of
Health Information Directory to record hospital contacts
and contact with mental health services. The National
Minimum Dataset contains routinely collected informa-
tion on all hospital discharges in New Zealand linked to
a patient’s individual National Health Index number.
Outcome measures (Table 1)
The primary outcome measure is hospital repetition for
self-harm during the year after the index presentation.
The secondary outcome measures are:
1. Self reported repetition for self-harm assessed at
three months and one year.
2. Hopelessness measured by the Beck Hopelessness
Scale at baseline, three months and one year.
3. Depression and anxiety measured by the Hospital
Anxiety and Depression Scale at baseline, three
months and one year.
4. Overall mortality (that is suicide deaths plus other
causes of death) and suicide deaths at three months,
one year, five years and ten years.
5. Costs after the index presentation including health
service use, costs of attending care, cost of medica-
tion and time off work at three months and one
year.
6. Quality of life and social function as measured by
the EQ-5D (http://www.euroqol.org/) and the SF36
at baseline, three months and one year.
Outcome measures will be collected in several differ-
ent ways.
Self rating
Rating scales will be by self rating.
DHB records
We will inspect these for episodes of repetition and
health service use including face to face contact with
mental health services and hospital admissions.
Ministry of Health Information Directorate
National Minimum Dataset (http://www.moh.govt.nz/
moh.nsf/indexmh/dataandstatistics-collections-nmds)
and Mortality Collection (http://www.moh.govt.nz/
moh.nsf/indexmh/dataandstatistics-collections-mortality)
We will inspect these for health service use (both gen-
eral and mental health), hospital representation for self-
harm and for mortality data. (It is necessary to look at
national data on these measures as we found in our pre-
vious trial that at least 50% of people who self-harm
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DHB where they presented).
Self report by structured interview
Information for the economic analysis and self report of
repetition will be gathered by telephone interview at
three months and one year after the index attempt (see
Additional File 3 for pro forma). Telephone interviewers
will be blind to the allocation of subjects. Blinding will
be tested by asking the interviewers to nominate which
group the subject was enrolled in. The economic analy-
sis will also use a brief measure of quality of life the
EQ-5D and interviewers will ask about health service
use; costs associated with this; time off work; time off
work for family to care for the participant; changes in
benefit; changes in occupation; and drug use and cost.
Participants will have the option of completing these
measures in a face to face interview if, for example, they
do not have a phone.
Process evaluation
A process evaluation will explore the implementation,
receipt and context of the intervention with a view to
helping understand the results in accordance with the
Medical Research Council’s guidelines[19] on assessing
complex interventions. This will describe the processes
in the intervention and control groups, provide informa-
tion about the contexts in which the treatments are
delivered and supply information about the experience
of being part of the trial. The process evaluation is
described in Table 2 below. The self-harm teams will
also receive weekly supervision, the main themes of
which we will incorporate into the process evaluation.
Process evaluation analysis
Numerical data will be entered into the Clinical Trials
Research Unit web based data entry system specifically
designed for this study. Information from the examination
of patient notes and audiotapes will be used to assess the
adherence of therapists to the manual in a 10% random
sample of those who completed problem solving therapy.
Data from structured interviews and focus groups will be
analysed for emergent themes using NVIVO.
Statistical methods
Power analysis
We know from our previous study that people who
agree to receive problem solving therapy have a hospital
repetition rate at one year of about 13%. The rate of
repetition in people who receive usual care is about 20%
- that is a relative risk reduction of 35% which would be
clinically important. To demonstrate that such a differ-
ence is unlikely to be due to chance at a significance
level of 0.05 with 80% power we will need to recruit 440
people into each arm of the trial. In the two Auckland
Table 1 Outcome measures
Outcome
measure
Description Explanation Administered
Primary
Hospital
repetition of
self-harm
Data on hospital contacts from participating DHB’s and the New
Zealand Health Information Service National Minimum Dataset
Three and twelve
months
Secondary
Hopelessness Beck Hopelessness Scale (BHS)[22] Best predictor of subsequent self-harm. Scores on a range of 0
to 20 with higher scores indicating greater hopelessness.
Baseline, three and
twelve months
Depression and
anxiety
Hospital Anxiety and Depression Scale
(HADS)[23]
Self report scale. Scores of 10 and above on the anxiety and
depression sub scales indicate clinically significant symptoms.
Baseline, three and
twelve months.
Health status EQ-5D [24] A generic health-related quality of life index that can be related
to costs.
Baseline, three
months and twelve
months
Self report
repetition of
self-harm
Self report assessed by telephone interviewer blind to allocation Three and twelve
months
Social
functioning
SF-36 [25] A generic measure of functional health and well being Baseline, three and
twelve months
Sense of
belonging
Sense of belonging instrument (SOBI)
[26]
Self report scale on sense of belonging to a community and
ethnicity
Baseline, three and
twelve months
Seriousness of
suicide attempt
Self rated objective part of the Beck
Suicide Intent Scale (BSIS)[27]
Self report scale indicating the degree of suicidal intent of the
self-harm episode
Baseline
Costs following
index attempt
Health service use, costs of attending
care, cost of medication and time off
work
Self report assessed by telephone interviewer blind to allocation Three and twelve
months
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land conservatively 1450 people present with self-harm
a year [20]. Reducing this figure by 15% (which is the
proportion who would be under 17) would mean a
potential pool of about 1200 eligible people a year of
whom 600 (50%) would agree to be in a trial, so 900 in
18 months. This number will also have enough power
to detect a 50% reduction in overall mortality at 5 and
10 years (from 10% to 5%). We will apply for further
funding to allow follow up of this cohort.
Analysis
Statistical analysis will be by the biostatistics team of the
Auckland Clinical Trials Research Unit (CTRU).
Data from the trial will be entered into an Oracle
database at the CTRU and extracted into SAS for analy-
sis. All statistical analyses will be performed using SAS
version 9.2 (SAS Institute Inc. Cary NC). All statistical
tests will be two-tailed and a 5% significance level main-
tained throughout the analyses. Assessment of baseline
comparability of the intervention and control group will
be carried out via descriptive analyses for demographic
information, method of self-harm and previous history
of self-harm. The proportion of people repeating self-
harm in each group will be analysed using chi-squared
test. The number of self-harm re-presentation episodes
for the hospital and self report outcomes during follow-
up will be analysed using negative binomial regression.
Kaplan-Meier curves and Cox proportional hazards
regression modeling will be used to analyze time to first
re-presentation to hospital for self-harm and time to
event for the mortality outcomes. The change from base-
line to 3 months and one year in each of the repeated
continuous outcomes will be analysed using mixed
model regression. If baseline characteristics are found to
be substantially different between the groups we will
adjust for these in the regression modeling. All analyses
will be conducted on patients who are randomised and
consented except for the re-presentation to hospital and
time to re-presentation outcomes which will be an inten-
tion to treat analysis that includes all randomised patients
including those that did not consent. (This is because
information on these outcomes are routinely collected in
New Zealand as part of the National Minimum Dataset).
We plan to analyse those with and without a history of
self harm at the index episode together and separately.
In addition sensitivity analyses will be conducted using
a CACE analysis[21] where appropriate which takes into
account the fact that after randomisation not everyone
in a Zelen design agrees to take part in the study. This
has the effect of diluting any treatment effect and intro-
ducing a possible self selection bias. A CACE analysis is
an attempt to correct for this.
Cost effectiveness analysis
We aim to collect the following data from all patients in
the trial at three months and one year after the date of
their index attempt. The data will be collected by a
research assistant by telephone interview with the
patients, by examination of routinely collected health
data and liaison with the finance departments of the
relevant health care providers.
Costs to patients
￿ Time off work
￿ Distance travelled for treatment for all disorders
￿ Time taken for treatment
￿ Costs for attending general practice - travel, pay-
ment to general practice, time off work
￿ Costs of family to attend treatment or provide sup-
port for the patient (for example taking time off
work to be with the patient)
￿ Cost of medication
￿ Benefits claimed
Costs to health care provider
￿ Staff salaries for providing treatment including the
problem solving therapy (therapist and in-patient
treatment)
Table 2 Process evaluation in ACCESS
Data collection method Data collected
Programme documentation and
observation (to assess fidelity, dose
and reach)
Number of sessions of patient
support
Number of PST sessions
Completion of PST
Audiotaping of PST sessions
Examination of written client PST
research records
Number of clients where sense of
belonging addressed in PST
Use of GP voucher
Number of postcards sent
Summary of discussions around
adverse events
Proportion of clients who received
the interventions in each centre
Structured interviews (to assess
barriers, facilitators and suggestions
for improvement)
Interview research clinicians re
barriers and facilitators to the
interventions plus suggestions for
improvement
Interview purposive sample of
patients re what helped and what
did not help plus suggestions for
improvement
Twelve month telephone
interview of all patients what
helped and what did not help
Interview GP’s who saw clients
through GP voucher to assess
their perception of the
intervention and suggestions for
improvement
Interview focus group of staff in
mental health services re barriers
and facilitators to interventions
plus suggestions for improvement
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￿ Cost of treatments - for example care in intensive
care or burns unit, cost of medication
￿ Overheads
Analysis All analyses will be carried out on an inten-
tion-to-treat basis for total costs over three months and
one year. We will perform multiple regression to adjust
for baseline characteristics including age, sex, number of
previous attempts and Beck Hopelessness Score. We
intend to perform an incremental analysis of costs and
consequences using the primary outcome measure as
the number of repetitions averted. From this we will
produce cost-effectiveness acceptability curves for the
intervention.
We also intend to perform a sensitivity analysis to test
how the costs and consequences of self-harm change
within a range of costs for the different economic
inputs. We anticipate that the model will be most sensi-
tive to changes in the costs of in-patient medical care.
We will also test the sensitivity of the results to produc-
tivity losses and costs of mental health treatment.
Termination of the study
Termination will be considered if there is 10% absolute
greater number of adverse events (re-presentations to
hospital for self-harm) in the treatment group than in
the usual care group at three months. Suicides will be
reported to the relevant ethics committee. Unblinded
analyses to assess excess harm will be conducted at one
year by an independent statistician at CTRU (not the
study statistician). One year was chosen as any shorter
time will mean that there will be few outcomes and any
longer time is close to the end of the intervention at
18 months. For this analysis the Haybittle-Peto stopping
boundary will be used which is based on a three stan-
dard deviation rule corresponding to a two sided test
P = 0.003 stopping rule. This does not affect the power
calculation of the study.
Discussion
The study, due to report its findings in 2012, tests the
effectiveness of a complex package of interventions in
the management of people who present to hospital with
intentional self-harm. It uses a novel design to try and
overcome the problems of previous trials which have
recruited small numbers of unrepresentative people. A
strength of the study is that it is a pragmatic trial which
aims to recruit large numbers and does not exclude
people if English is not their first language. The analysis
of the primary outcome is a true intention to treat ana-
lysis of everyone randomised not just those who agree
to the intervention. This provides greater information
about the impact of the intervention when introduced
into a service compared to a standard randomised
controlled trial. A potential limitation is the analysis of
the results which is complex and may underestimate
any effect on the secondary outcomes if a large number
of people refuse their consent in the group randomised
to problem solving therapy as they will effectively cross
over to the treatment as usual group.
Additional material
Additional file 1: Card letting people know they will be contacted.
Additional file 2: Postcard.
Additional file 3: Follow up telephone interview proforma.
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